ZYNRELEF Market Size, Forecast, and Market Insight - 2032

"ZYNRELEF Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about ZYNRELEF for Postoperative pain in the seven major markets. A detailed picture of the ZYNRELEF for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ZYNRELEF for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZYNRELEF market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

ZYNRELEF (formerly known as HTX-011) (bupivacaine and meloxicam) contains bupivacaine, a local amide anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), and is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 h after a bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. It is the first and only extended-release dual-acting local anesthetic (DALA) and delivers 72 h of postoperative pain relief via a single needle-free application. It is formulated in Heron's proprietary controlled-diffusion Biochronomer polymer for consistently regulated delivery of bupivacaine and meloxicam.

Dosage and administration

The recommended dose of ZYNRELEF is as follows:

• For bunionectomy: up to 2.3 mL to deliver 60 mg of bupivacaine and 1.8 mg of meloxicam.
• For open inguinal herniorrhaphy: up to 10.5 mL to deliver 300 mg of bupivacaine and 9 mg of meloxicam.
• For total knee arthroplasty: up to 14 mL to deliver 400 mg of bupivacaine and 12 mg of meloxicam.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ZYNRELEF description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on ZYNRELEF regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ZYNRELEF research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around ZYNRELEF.
• The report contains forecasted sales of ZYNRELEF for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for ZYNRELEF in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZYNRELEF Analytical Perspective by DelveInsight

• In-depth ZYNRELEF Market Assessment

This report provides a detailed market assessment of ZYNRELEF for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• ZYNRELEF Clinical Assessment

The report provides the clinical trials information of ZYNRELEF for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZYNRELEF dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to ZYNRELEF and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZYNRELEF in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of ZYNRELEF from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZYNRELEF in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of ZYNRELEF?
• What is the clinical trial status of the study related to ZYNRELEF in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZYNRELEF development?
• What are the key designations that have been granted to ZYNRELEF for Postoperative pain?
• What is the forecasted market scenario of ZYNRELEF for Postoperative pain?
• What are the forecasted sales of ZYNRELEF in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ZYNRELEF for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?